We would like to thank the rest of the Trustees, the CEO, and the leadership group for their outstanding work in progressing the UKKA into the organisation it is today. We thank all colleagues who are contributing within and outside the UKKA, we believe one of our great strengths is the breadth of leadership and we see so many colleagues making major contributions to the development of the UKKA. Our membership is growing as is the range and depth of work that is being undertaken.

Professional Groups
The UKKA is made up of members from a variety of professions which is to the benefit of all members. Most professional groups are now full members of the UKKA. The Paediatric Nephrology Nurses Group have committed to UKKA as a full-member organisation, and the Association of Renal Technicians and the Renal Nutrition Group are working towards this. We are continuing to work with the Association of Nephrology Nurses UK (ANN UK) to define the relationship between UKKA and ANN UK.

Over the past year, we have established a partnership framework with the International Society of Nephrology (ISN) that has several workstreams, from Sustainable Kidney Care to Young Nephrologists. We are supporting the ISN to develop their framework for the multi-professional team. There is an outstanding membership offer to join the ISN for UKKA members. We will work to continue to extend the membership benefits of UKKA and partner with other related societies and associations.

Leadership and mentorship
2022 saw the planning and implementation of a leadership course with the Royal College of Physicians to support the development of more senior leaders within the UKKA membership. This was for 40 colleagues and was fully subscribed. All course members had a mentor from within the UKKA leadership group. This first cohort had representation from across the whole MPT and feedback indicates that they found it a positive and helpful course. We are hoping that many of the attendees will go on to take up leadership roles within the UKKA.
**Workforce**
Members of the UKKA remain under intense pressure and ensuring appropriate staffing and skill mix is a constant challenge across renal services.

The Renal Pharmacy Group is sponsoring a member to undertake an MSc looking at the workload for a pharmacist undertaking medicines reconciliation on a renal ward to aid workforce planning.

The [Renal Workforce document](#) is currently being updated with input from all professional groups. This document provides a robust outline to support the implementation of national workforce planning directives.

**Partnership with the NHS**
The UKKA has been working closely with the Renal Services Transformation Programme (RSTP) and the National Clinical Director to discuss ongoing work, optimise communication and ensure the correct personnel are involved.

**Devolved nations**
We have set up regular meetings with leadership in the devolved nations and are continuing to work to ensure that the devolved nations have a full voice and representation in the UKKA.

**Equality, diversity and inclusion**
We continue to be committed to creating and sustaining a positive, fair and mutually supportive environment. We accept, respect and value people with diverse identities and backgrounds and believe our differences make us stronger and more effective in achieving our goals. We ensure appointments are made on the recommendation of a transparent, balanced and appropriate panel, are made on the basis of merit, and encourage applications from all suitably qualified and eligible candidates.

We recognise that this is a key area of work, and an EDI committee has been established to ensure that these values run throughout the UKKA.

**UK Kidney Week**
We thank the Programme Committee Chairs, the wider Programme Committee and the UKKA Secretariat for an outstanding 2022 meeting in Birmingham, the first UKKW to be held in-person after the COVID-19 pandemic. The organisation of the event was brought in-house and saw a closer relationship with the Programme Committee, suppliers and industry sponsors. There were around 650 in-person delegates and over 1000 on the livestream. A fantastic percentage of MPT colleagues attended the conference this year. Lessons learned are now being applied to planning for future UK Kidney Weeks.
Kidney Quality Improvement Partnership (KQIP)
We are delighted with the continuing development of KQIP, with outstanding programme managers and with the clinical leadership of Rosie Donne and Udaya Udayaraj. Relationships with the regional renal networks are maturing and the partnership models with patient charities and industry are well established, supported in DAYLife by Kidney Care UK and Fresenius, and with Kidney Care UK committing to the funding of an Advanced Kidney Care workstream. KQIP has a comprehensive programme of work planned for 2023 and beyond.

Executive team and trustee roles
There have been changes to our current leadership team this year. We would like to express thanks for their hard work and commitment to the UKKA. Sharlene Greenwood demitted from the MPT President post and became Past-President for a year. Our new MPT President is Clare Morlidge, a renal pharmacist and past Chair of the UK Renal Pharmacy Group, who took up her post in June. We are very grateful for the wisdom and guidance of Heather Lawrence and David Silver, our Non-Member Trustees

Clare Morlidge
President, the UKKA

Prof Paul Cockwell
President, the UKKA
GOVERNANCE AND STRUCTURE

The board of trustees is the UK Kidney Association’s governing body as a charity. It is responsible for the management of the UK Kidney Association’s business, for which purpose they may exercise all the powers of the UK Kidney Association. The board meets face to face at least three times a year to:

- Manage risk
- Oversee strategy, define policy, agree the business plan and monitor progress
- Ensure the proper management of the assets of the Renal Association for the benefit of the objects.

It has the authority to carry out the charitable responsibilities of the UK Kidney Association and delegates the operational aspects of its affairs to its CEO and committees. It works closely and liaises with the UK Kidney Association Council but ultimately, all decisions (apart from changes to the Articles of Association) are either taken by, or on behalf of, the Board of Trustees and reported to the membership at the annual general meeting.

TRUSTEES

PRESIDENT
Prof Paul Cockwell
Queen Elizabeth Hospital Birmingham

PRESIDENT
Clare Morlidge
Lister Hospital

PAST-PRESIDENT
Dr Sharlene Greenwood
King’s College Hospital

BAPN PRESIDENT
Dr Jan Dudley
Bristol Royal Hospital for Children

HONORARY SECRETARY
Prof Alan Salama
Royal Free Hospital London

TREASURER
Prof Claire Sharpe
King’s College London
NON-MEMBER TRUSTEE
Heather Lawrence

NON-MEMBER TRUSTEE
David Silver

SENIOR MANAGEMENT TEAM

CEO
Ron Cullen

DIRECTOR OF INFORMATICS RESEARCH
Professor Dorothea Nitsch

UKRR MEDICAL DIRECTOR
Dr James Medcalf

UKRR HEAD OF OPERATIONS
Dr Retha Steenkamp
STRUCTURE

THE SIX PILLARS OF THE UKKA
COMMITTEES & SPECIAL INTEREST GROUPS

Clinical and Academic Committees continue to meet the needs of UK Kidney Association members. Central to delivery, the UKKA is focused on the creation of a series of multi-professional Special Interest Groups (SIGs) supported and enabled through core UKKA corporate structures.

Committees & Chairs

- Clinical Practice Guidelines Committee - Prof James Burton & Katie Fielding
- International Committee - Prof Sunil Bhandari
- Clinical Services Committee - Dr Marie Condon
- Education and Training Committee - Prof Debasish Banerjee
- Patient Safety Committee - Dr Katrin Jones & Karen Jenkins
- Patient Information Committee - Dr Rebecca Suckling
- Renal Scientists Committee - Prof Tim Bowen
- Sustainable Kidney Care Committee - Dr Suren Kanagasundaram
- Rare Diseases Committee - Prof Danny Gale
- Infection Prevention & Control Committee - Dr Katie Vinen

Special Interest Groups & chairs

- Acute Kidney Injury - Dr Jon Murray & Clare Morlidge
- Chronic Kidney Disease - Prof Paul Cockwell
- Home Dialysis - Dr Mark Lambie & Stephanie Walker
- Living Well With Kidney Disease - Dr Rosa Montero & Helena Jackson
- Supportive Care - Karen Jenkins & Dr Katie Vinen
- Diagnostic Interventional Nephrology - Dr Saeed Ahmed
- Transition to Young Adult - Dr Arvind Nagra
In 2022, members of the UKKA comprised over 1,641 doctors, scientists and MPT members.
OUR MEMBERS

AWARDS, BURSARIES & LECTURES

Raine Award
This prestigious award is made to a relatively junior member who has made a significant contribution to research. In 2022, this was awarded to Dr Jennifer Lees, at UK Kidney Week.

Lockwood Award
The Lockwood Award is awarded to help RA members present work, combined with a visit to a collaborating laboratory or clinical nephrology unit overseas. In 2022 this was not awarded.

Walls bursaries
These bursaries enable a clinician and non-clinician to spend short periods at other centres, generally outside the UK. In 2022 this was not awarded.

Medical student elective bursaries
The UK Kidney Association awards 8 bursaries to medical students who are planning to undertake electives which include a significant renal component, either clinical or research. In 2022 no bursaries were awarded.

O'Donoghue Lecture
This lecture is named in honour of the UKKA's former President Professor Donal O'Donoghue OBE. In 2022 this lecture was delivered by Dr June Raine, at UK Kidney Week.

Chandos Lecture
This lecture honours the Chandos family who have given great support to the kidney community over many years. This lecture was not delivered in 2022.

de Wardener Lecture
The de Wardener lecture was established in 2004 in honour of Professor Hugh de Wardener (1915-2014), one of the UK’s most distinguished nephrologists and clinical scientists. This lecture was not delivered in 2022.

Osman Lecture
The Osman Lecture was endowed by Mrs Ruth Osman, widow of Dr Arnold Osman, a founding member and the first President of the Renal Association who died in 1972. This lecture was not delivered in 2022.

Jane Macdonald Leadership Award
For outstanding leadership in the renal community. This was not awarded in 2022.

Donna Lamping Researcher Award
For outstanding research in Kidney Care. This was not awarded in 2022.

Mallick Lecture Award
For lifetime services to the renal community. This was not awarded in 2022.
CONSULTATIONS

The UK Kidney Association has been involved in a number of NICE consultations in the last year. Thank you to all members who contributed.

- Vasculitis (anti-neutrophil cytoplasmic antibody) - avacopan (maintenance) [ID1581] – Alan Salama
- Roxadustat for treating anaemia in adults with chronic kidney disease [ID1483] - Sunil Bhandari
- Cytomegalovirus infection (refractory, resistant) - maribavir (after transplant) [ID3900] - Andrea Devaney
- Voclosporin with immunosuppressive therapies for treating lupus nephritis [ID3962] – Isaac Tseng
- Technical engagement (Stakeholders) Chronic kidney disease (diabetes type 2) – finerenone [ID3773] – Indranil Dasgupta & the ABCD Committee
- Single Technology Appraisal: Voclosporin with immunosuppressive therapies for treating lupus nephritis [ID3962] – Ruth Pepper
- Single Technology Appraisal: Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672] - Michelle Willicombe
- NICE indicators on chronic kidney disease - David Wheeler, Sunil Bhandari & Paul Cockwell
- Multiple Technology Appraisal (MTA) Therapeutics for people with COVID-19 Stakeholder Information Meeting [ID4038] - Alan Salama & Steve McAdoo
- NICE Appraisal Consultation Document (ACD): consultees and commentators: Chronic kidney disease (diabetes type 2) – finerenone [ID3773] – Indranil Dasgupta & the ABCD-UKKA Committee (Andrew Frankel, Steve Bain, Debasish Banerjee)
- Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787] - Virtual Committee Meeting – Jan Dudley
- Highly Specialised Technologies (HST): Lumasiran for treating primary hyperoxaluria type 1 [ID3765] - Shabbir Moochhala
- Slow-release potassium bicarbonate-potassium citrate for treating distal renal tubular acidosis [ID3787] - Detlef Böckenhauer
- Daprodustat for treating anaemia in adults with chronic kidney disease [ID3987] – Sunil Bhandari
- Difelikefalin for treating pruritus in people having haemodialysis [ID3890] – Indranil Dasgupta, James Burton
CONSULTATIONS

- Technology Appraisal Advisory Committee Meeting Vasculitis (anti-neutrophil cytoplasmic antibody) – avacopan [ID1581] – **Alan Salama**

- Scoping Consultation Invitation (All C&C): Nephropathy (IgA) - budesonide (targeted-release) [ID1434] – **Chee Kay Cheung**


- MTA: Therapeutics for people with COVID-19 [ID4038] – **Liz Lightstone**


- Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900] – **Andrea Devaney**

- Highly Specialised Technologies Evaluation Committee Meeting: Lumasiran for treating primary hyperoxaluria type 1 [ID3765] - **Shabbir Moochhala**

- NICE indicators on chronic kidney disease – **Sunil Bhandari**

- Draft acute kidney injury (AKI) quality standard – update – **Karen Nagalingam**

- Draft manual on 'Developing NICE guidelines: the manual' – **Mark Devonald**

- Technical engagement (Stakeholders): Chronic kidney disease (diabetes type 2) – finerenone [ID3773] – **Helen Haley**

- Technical engagement to stakeholders: Vasculitis (anti-neutrophil cytoplasmic antibody) [ID1581] – avacopan – **Clare Morlidge**

- Single Technology Appraisal: Voclosporin with immunosuppressive therapies for treating lupus nephritis [ID3962] – **Isaac Tseng**

- Multiple Technology Appraisal (MTA) - Therapeutics for people with COVID-19 Stakeholder Information Meeting [ID4038] – **Clare Morlidge, Andrea Devaney, Hayley Wells**

- Single Technology Appraisal: Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900] – **Andrea Devaney**


- Technology Appraisal Advisory Committee Meeting Vasculitis (anti-neutrophil cytoplasmic antibody) – avacopan [ID1581] – **Clare Morlidge**
Professor Timothy Bowen, Trustee with Financial Governance Responsibility

The UK Kidney Association (UKKA) had an overall surplus for 2022 of £65,533 (2021: £1,047,985).

2022 was a year of integration within the organisation following the merger of the British Renal Society (BRS) and the Renal Association to form the UK Kidney Association. With more professional groups joining, we continued to grow into the leading professional body for kidney disease. The Paediatric Nephrology Nurses Group (PNNG) joined the UKKA in 2022, dissolving as a CIC and transferring assets totalling £7,537 and this amount is included in the surplus.

UK Kidney Week took place in Birmingham as a hybrid event and was one of our most well-attended meetings, with over 1,900 delegates registered. Organised solely by our internal team, we developed the skills of our own staff to build improved relationships with industry and to offer an exceptional service to our delegates in-person and online.

Overall, the UKKA is financially very secure. The agreed reserve level for 2022 was £3.9 million to be held either as immediately available funds or in short to medium-term investments. The reserves at the end of 2022 were £3,622,963 (2021: £3,557,430). The reserves held are sufficient to cover 12 months operating costs and the agreed level will be reduced slightly in 2023 to reflect the actual required levels whilst remaining liquid.

Income from investments increased to £9,533 (2021: £7,537).

The pie charts give an overview of the streams of income received by the UKKA and how the money is then spent. For further details please see the annual accounts which are available via Companies House from October 2023.
Expended:
- Staff: 56%
- Professional Services: 20%
- Meeting Costs: 9%
- IT: 9%
- Office Costs: 4%
- Finance: 0%

Income:
- Capitation: 53%
- Income: £4,123,522
- Memberships: 4%
- Scientific Meetings: 5%
- Other Income: 16%
- Events: 9%
- Grants: 4%
- Asset Transfers:
- Other Income: 16%
- Scientific Meetings: 5%
- Project Work: 2%
- Grants: 2%
- Interest & Donations: 6%
- Memberships: 4%
- Interests & Donations: 6%
- Project Work: 2%
- Memberships: 4%
- Other Income: 16%

Disclaimer
The data reported here have been supplied by the UKKA however the interpretation and reporting of the data are the responsibility of the author.
Equality and diversity
The UK Kidney Association continues to be committed to creating and sustaining a positive, fair and mutually supportive environment. We accept, respect and value people with diverse identities and backgrounds and believe our differences make us stronger and more effective in achieving our goals. We ensure appointments are made on the recommendation of a transparent, balanced and appropriate panel, are made on the basis of merit, and encourage applications from all suitably qualified and eligible candidates.

Legal status
The Renal Association (trading as the UK Kidney Association) is registered in England and Wales as Company 2229663, limited by guarantee and registered as charity number 800733.

Articles and rules
You can read the articles and rules here.